Summit Therapeutics/SMMT

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Ticker

SMMT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Miami, United States

Employees

105

SMMT Metrics

BasicAdvanced
$5.3B
Market cap
-
P/E ratio
-$0.17
EPS
-1.13
Beta
-
Dividend rate
$5.3B
-1.13
6.966
6.725
239.364
247.731
-5.87%
-33.27%
-130.59%
119.72
125.02
-9.29
-92.73%
-42.56%

What the Analysts think about SMMT

Analyst Ratings

Majority rating from 3 analysts.
Buy

SMMT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$43M
18.90%
Profit margin
0.00%
NaN%

SMMT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.00%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.06
-
Expected
-$0.06
-$0.06
Surprise
0.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Summit Therapeutics stock?

Summit Therapeutics (SMMT) has a market cap of $5.3B as of July 04, 2024.

What is the P/E ratio for Summit Therapeutics stock?

The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of July 04, 2024.

Does Summit Therapeutics stock pay dividends?

No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Summit Therapeutics dividend payment date?

Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.

What is the beta indicator for Summit Therapeutics?

Summit Therapeutics (SMMT) has a beta rating of -1.13. This means that it has an inverse relation to market volatility.

Buy or sell Summit Therapeutics stock

Buy or sell Summit Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing